---
title: "Wegovy (semaglutide), all indications: Drug interactions questions"
description: "Drug interactions questions on Wegovy (semaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Wegovy have? Does Wegovy make birth control pills less effective? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/wegovy/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide), all indications: Drug interactions questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)

## Drug interactions

<a id="wegovy-drug-interactions"></a>

### What drug interactions does Wegovy have?

> “WEGOVY<sup>®</sup> lowers blood glucose and can cause hypoglycemia. 
> The risk of hypoglycemia is increased when WEGOVY<sup>®</sup> is 
> used concomitantly with insulin or insulin secretagogues (e.g., 
> sulfonylureas). The addition of WEGOVY<sup>®</sup> in patients treated with 
> insulin has not been evaluated.
> When initiating WEGOVY<sup>®</sup>, consider reducing the dose of 
> concomitantly administered insulin secretagogue or insulin to 
> reduce the risk of hypoglycemia [see Warnings and Precautions 
> (5.4), Adverse Reactions (6.1)].”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “WEGOVY<sup>®</sup> causes a delay of gastric emptying and thereby has the potential to impact the absorption 
> of concomitantly administered oral medications. In clinical pharmacology trials with semaglutide 
> 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered 
> medications [see Clinical Pharmacology (12.3)]. In a drug interaction study with the semaglutide 
> tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral 
> medications concomitantly administered with WEGOVY<sup>®</sup>. Consider increased clinical or laboratory 
> monitoring for medications that have a narrow therapeutic index or that require clinical monitoring.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “In Vitro Studies: Semaglutide has very low potential to inhibit or induce CYP enzymes, and to inhibit 
> drug transporters.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

<a id="wegovy-birth-control-pills"></a>

### Does Wegovy make birth control pills less effective?

> “Clinical Studies and Model-Informed Approaches: The delay of gastric emptying with semaglutide 
> may influence the absorption of concomitantly administered oral drugs [see Drug Interactions (7.2)]. 
> Trials were conducted to study the potential effect of semaglutide on the absorption of oral drugs 
> taken with semaglutide tablets administered orally at steady-state exposure.
> •	Levothyroxine: Total thyroxine (i.e., adjusted for endogenous levels) AUC of was increased 
> by 33% following administration of a single dose of levothyroxine 600 mcg concomitantly 
> administered with oral semaglutide. Maximum exposure (Cmax) was unchanged.
> •	Other Drugs: No clinically significant differences in semaglutide pharmacokinetics were 
> observed when used concomitantly with omeprazole. No clinically significant differences 
> in the pharmacokinetics of the following drugs were observed when used concomitantly 
> with semaglutide: lisinopril, S-warfarin, R-warfarin, metformin, digoxin, ethinyl estradiol, 
> levonorgestrel, furosemide or rosuvastatin.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “In clinical pharmacology trials with semaglutide 
> 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered 
> medications [see Clinical Pharmacology (12.3)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

Note: The first passage describes drug interaction trials with Wegovy tablets and the second trials with semaglutide 1 mg once-weekly injection.

## Related pages
- [Medical information: Wegovy (semaglutide): All indications](https://www.evicenter.com/medical-information/wegovy)
- [Indication](https://www.evicenter.com/medical-information/wegovy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/wegovy/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/wegovy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/wegovy/storage-and-supply)
